/Idexx%20Laboratories%2C%20Inc_%20phone%20and%20logo-%20by%20T_Schneider%20via%20Shutterstock.jpg)
Valued at a market cap of $50.7 billion, IDEXX Laboratories, Inc. (IDXX) is a global leader in veterinary diagnostics and software solutions. Headquartered in Westbrook, Maine, the company develops and distributes products and services for companion animal veterinary, livestock and poultry, dairy, and water testing markets. IDEXX operates through three primary segments: Companion Animal Group (CAG), Water, and Livestock, Poultry, and Dairy (LPD).
The veterinary giant is ready to announce its fiscal Q3 earnings for 2025 before the market opens on Monday, Nov. 3. Before this event, analysts project the company to report a profit of $3.14 per share, up 12.1% from $2.80 per share in the year-ago quarter. The company has surpassed Wall Street’s bottom-line estimates in each of the last four quarters.
For the current year, analysts expect IDXX to report EPS of $12.61, up 18.2% from $10.67 in fiscal 2024. Its EPS is expected to further grow 12.3% annually to $14.16 in fiscal 2026.
IDXX shares have climbed 33.2% over the past year, surpassing the S&P 500 Index's ($SPX) 13.4% return and the Health Care Select Sector SPDR Fund’s (XLV) 8% downtick over the same time frame.
On Aug. 4, shares of IDXX skyrocketed 27.5% after the company released its stellar second-quarter earnings. It reported quarterly revenue of $1.1 billion, marking a 10.6% increase year over year and surpassing consensus estimates by 3.7%. Its earnings per share surged 48.8% from the same quarter last year to $3.63, exceeding analyst expectations by 9.7%. Highlighting its strong profitability, the company also raised its fiscal 2025 EPS guidance to a range of $12.40–$12.76, reinforcing investor confidence.
Wall Street analysts are moderately optimistic about IDXX’s stock, with a "Moderate Buy" rating overall. Among 13 analysts covering the stock, six recommend "Strong Buy," one indicates a "Moderate Buy," and six advise "Hold.” The mean price target for IDXX is $722.36, indicating a 13.4% potential upside from the current levels.
